Skip to main content
. 2020 Feb 18;12(2):466. doi: 10.3390/cancers12020466

Figure 3.

Figure 3

Effect of venetoclax on MDR in transfected ABCG2-overexpressing cells. (A) IC50 of mitoxantrone in HEK293 transfected cells with/without venetoclax and KO143. (B) IC50 of SN-38 in HEK293 transfected cells with/without venetoclax and KO143. (C) IC50 of topotecan in HEK293 transfected cells with/without venetoclax and KO143. (D) IC50 of cisplatin in HEK293 transfected cells with/without venetoclax and KO143. Columns with error bars represent mean ± SD from 3 independent triplicate experiments. Asterisks (*) indicate p < 0.05 versus control group (HEK293/pcDNA3.1 or untreated resistant cells).